Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased and priced at the high end of the range. Kailera is an advanced clinical-stage biotechnology company that says it is “focused on elevating the next era of obesity care.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRA: